You are leaving our website

or Decline

Our Financial Highlights for 2024

These are the primary measures used by management to monitor business performance, against both short-term budgets and forecasts and longer-term strategic plans.

To view in detail view our 2024 Annual Report

currently counter number sum counter number

See-through revenue*

currently counter number sum counter number

GM%: (Overall)

currently counter number sum counter number

Underlying EBITDA

currently counter number sum counter number

Underlying Profit Before Tax

currently counter number sum counter number

Underlying Basic EPS**

currently counter number sum counter number

Free Cash Flow*

currently counter number sum counter number

Leverage

currently counter number sum counter number

Net Debt

Please view our five year financial summary below

Five Year Summary
Year ended 31 December 2020 £mYear ended 31 December 2021 £mYear ended 31 December 2022 £mYear ended 31 December 2023 £mYear ended 31 December 2024 £m
Revenue129.8163.2167.4180.7178.8
Operating profit before non-underlying items36.845.635.741.939.9
Non-underlying operating items(20.5)(24.0)(53.4)(80.3)(46.0)
Operating profit16.321.6(17.7)(38.4)(6.1)
Profit before tax before non-underlying items33.542.230.331.531.5
Profit before tax after non-underlying items13.018.2(23.1)(48.8)(14.5)
Intangible assets412.9413.8393.4300.0253.6
Tangible assets15.94.85.65.75.4
Current assets77.281.0105.5104.1104.3
Current liabilities30.240.647.040.636.7
Equity281.0282.5265.5217.9207.6
Average shares in issue (millions)531.1535.3539.5540.1540.5
Shares in issue at period end (millions)532.9538.2540.0540.4540.6
Earnings per share – basic (p)1.511.37(3.93)(6.13)(1.99)
Earnings per share – adjusted underlying basic (p)5.116.394.284.554.36

* Non-IFRS alternative performance measures (see note 31). See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.